Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Elizabeth Louise Van Der Kam

Sean Colm Turner

Michael Ochse

Achim Moeller

Martin Schmidt

Kevin B Sippy

Frauke Pohlki

Ramin Faghih

Wilfried Hornberger

Charles W Hutchins

Wilhelm Amberg

Udo Lange

Anil Vasudevan

Michael Schulz

Herve Geneste

Mario Mezler

Jürgen Dinges

Frank Oellien

Jeroen Van Bergeijk

Patrick Walleser

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Fused heterocyclic compounds as S1P modulators

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the &#x3b3;-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Land Gare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the &#x3b3;-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Substituted pyrazolopyrimidines and method of use

Growing community of inventors

Ludwigshafen, Germany

Elizabeth Louise Van Der Kam